The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin
Abstract
Rosuvastatin is a new HMG‐CoA reductase inhibitor with unique pharmacologic and pharmacokinetic properties. It has additional HMG‐CoA reductase enzyme‐binding interactions that cause tighter binding, has substantial active transport into hepatocytes, and has the lowest (LDL) for sterol synthesis in hepatocytes. Rosuvastatin 10 mg and 80 mg dosages have superior low‐density lipoprotein (LDL) cholesterol‐lowering efficacy as compared to atorvastatin 10 mg and 80 mg. Rosuvastatin 10 mg has also been shown to have superior LDL reductions to 20 mg of both simvastatin and pravastatin. This agent can raise high‐density lipoprotein (HDL) 8% to 12% and lower triglycerides by 10% to 35%. Rosuvastatin is a hydrophilic agent with poor penetration in extrahepatic tissue such as human umbilical vein endothelial cells and fibroblasts. It also has a low potential for cytochrome P450 drug interactions and can be dosed in the morning or night. In conclusion, rosuvastatin is an agent with molecular alterations that provide it with unique pharmacologic and pharmacokinetic effects. As such, it is a novel and unique HMG‐CoA reductase inhibitor for the treatment of hyperlipidemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Cited by
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Transporters as a determinant of drug clearance and tissue distribution
Shitara, Y., Horie, T., & Sugiyama, Y. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.003 · Cited by 496
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Metadata
- Authors
- White, C. M.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2002-09
- Volume
- 42
- Issue
- 9
- Pages
- 963-970
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2107347483
- Cited by
- 199
- References
- 6
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. https://app.cochat.ai/papers/10.1177/009127000204200902
- The paper
- White, C. M. (2002). A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. The Journal of Clinical Pharmacology. https://doi.org/10.1177/009127000204200902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.